HC Wainwright Reiterates “Buy” Rating for Entera Bio (NASDAQ:ENTX)

Entera Bio (NASDAQ:ENTX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 412.82% from the stock’s current price.

Entera Bio Price Performance

Shares of NASDAQ:ENTX opened at $1.95 on Tuesday. The company’s 50 day moving average price is $2.20 and its two-hundred day moving average price is $2.02. Entera Bio has a 12-month low of $1.30 and a 12-month high of $3.35. The firm has a market cap of $69.78 million, a PE ratio of -7.50 and a beta of 1.62.

Institutional Trading of Entera Bio

Several large investors have recently made changes to their positions in the company. Knoll Capital Management LLC boosted its position in shares of Entera Bio by 51.5% during the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock worth $12,470,000 after acquiring an additional 2,000,000 shares in the last quarter. Parkman Healthcare Partners LLC boosted its position in shares of Entera Bio by 2.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock worth $781,000 after acquiring an additional 9,558 shares in the last quarter. Northern Trust Corp acquired a new stake in shares of Entera Bio during the 4th quarter worth approximately $450,000. Finally, Perigon Wealth Management LLC acquired a new stake in shares of Entera Bio during the 4th quarter worth approximately $325,000. Institutional investors and hedge funds own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.